Meet us at

No upcoming event planned at this time

Latest news

First patient dosed in Synphora’s Phase II/III study of latanoprost as a treatment for Menière’s disease

October 16, 2013 - STOCKHOLM, Sweden. Synphora AB announced today that dosing has been initiated in a randomized, multicenter, double-blind Phase II/III study of latanoprost as a treatment for Menière’s disease. A total of 120 patients will be included in the trial.

The study has been designed to evaluate the effect and safety of latanoprost in treating the three cardinal symptoms of Menière’s disease: vertigo, tinnitus and hearing loss. Each symptom on its own is serious, but taken together they can have debilitating effect by severely curtailing daily activities of a patient’s normal life, including relationships with other individuals.

The study’s principal investigator, Dr Mikael Karlberg, Associate Professor, Lund University Hospital, says: “It is indeed gratifying to participate in the development of a potentially novel treatment for Menière’s disease where the medical community currently has little to offer in terms of therapeutic interventions. The drugs used today offer either no or limited benefits to the patient and in some cases may even negatively affect hearing.

“It is very pleasing to be able to move forward with our clinical development program. If our hypothesis is proven right, that latanoprost will be able to lower the pressure in the endolymphatic space and thus alleviate the course of Menière’s disease, then Synphora will have made a major contribution towards making available a truly meaningful treatment for the disease”, says Fredrik Henell, CEO of Synphora.

About Synphora

Synphora is a biopharmaceutical company focusing on the development of pharmacological treatments for diseases of the inner ear, in particular

  • Menière’s disease
  • Noise-induced tinnitus

The Company has now initiated a phase II/III clinical trial in Menière’s disease.

The current strategy is to build on the therapeutic principle of administrating a prostaglandin Freceptor agonist to the eye. This treatment has been successfully established and is in worldwide clinical use for the treatment of glaucoma for the last 25 years.

Menière’s disease is typically associated with a retention of fluid in the membranous labyrinth of the inner ear (“endolymphatic hydrops”). This is in analogy with glaucoma, where a buildup of intra-ocular fluid causes an elevation of intra-ocular pressure and as a consequence damage to the optic nerve. This is why Menière’s disease is often referred to as “glaucoma of the ear”.

There is a large body of experimental work suggesting that prostaglandin F receptor agonists are associated with a neuroprotective effect which is distinctly different and additional to their ability to lower the intra-ocular pressure by enhancing the drainage of fluid from the eye. This effect may work equally well for the treatment of noise-induced tinnitus.

For further information, please contact:

Fredrik Henell

CEO

Synphora AB

Phone: + 46 70 325 38 47

Email: fredrik.henell@synphora.com

Download as PDF

2013-10-16

First patient dosed in Synphora’s Phase II/III study of latanoprost as a treatment for Menière’s disease

October 16, 2013 - STOCKHOLM, Sweden. Synphora AB announced today that dosing has been initiated in a randomized, multicenter, double-blind Phase II/III study of latanoprost as a treatment for Menière’s disease. A total of 120 patients will be included in the trial. 

2012-03-11

Prosper Menière Society’s Gold Medal Award

March 11, 2012  - STOCKHOLM, Sweden. Synphora AB announced today that Professor Helge Rask-Andersen, Uppsala University Hospital, Uppsala, Sweden has been awarded the Prosper Menière Society’s Gold Medal Award for 2012.

2011-10-24

Synphora completes equity financing and William Gunnarsson joins the Board

October 24, 2011 - STOCKHOLM, Sweden. Synphora AB announced today that it has successfully completed an equity issue to fund the further development of its novel treatments for Menière’s disease and noise-induced tinnitus. There is currently no effective treatment for neither of these diseases.

William Gunnarsson representing BWG Holding, the lead investor in this financing round, will also join the Board of Directors of the Company.

Hemsida av Webbyrå KA Stockholm